focus -WSS

focus

author：knowledge 2025-10-01 18:33:01 - browse：47116

When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.

For more on what we cover, here’s where you can read Frank’s work; here’s more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Humana’s losses in Medicare Advantage tank its stock

knowledge

WSS

White House pharmacy plagued with problems, investigation finds

Merck CEO won’t testify in Senate, citing no expertise in drug prices

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

#NeedHerScience: shining a light on gender disparities in medicine

Venture capital firm's plans to take over Akron hospital face hurdles

Philips to halt sales of sleep apnea machines in U.S.

Wikipedia

focus

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

How generative AI ratchets up security threats for health systems

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The strategy behind pharma's lawsuits over drug pricing reform

The high cost of giving birth even with insurance

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Medicare details structure of new drug price negotiation program

New guidelines on severe brain injury complicate already difficult decisions

Medical leaders decry Supreme Court decision on affirmative action

Death of patient in Alzheimer’s trial raises question of possible risks

focus

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Gene therapy has helped boys walk. Can scientists keep it that way?

10 reasons why health care startups fail

Why drug prescriptions should include diagnoses

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Merck, Johnson & Johnson CEOs will testify on high drug prices

hotspot

knowledge

knowledge

focus